Table 1 Baseline characteristics and patient demographic of the study cohort
Characteristic | All patients (n = 158) | PICC-related DVT (n = 23) | Distant VTE (n = 23) |
|---|---|---|---|
Age (Mean) | 57 | 52 | 62 |
Gender | |||
Male | 56 (35.4%) | 7 (12.5%) | 9 (16%) |
Female | 102 (64.6%) | 16 (15.7%) | 14 (13.7%) |
Primary cancer | |||
Breast | 63 (39.9%) | 14 (22.2%) | 2 (3.1%) |
Colorectal | 78 (49.4%) | 8 (10.2%) | 17 (21.8%) |
Pancreas | 9 (5.7%) | 1 (11.1%) | 3 (33.3%) |
Other | 8 (5%) | 0 | 1 (12.5%) |
Treatment intention | |||
Neoadjuvant | 21 (13.3%) | 6 (28.6%) | 0 |
Adjuvant | 41 (26%) | 8 (19.5%) | 1 (2.4%) |
Palliative | 96 (60.7%) | 9 (9.3%) | 22 (23%) |
History of antiplatelet or anticoagulation | 14 (8.9%) | 2 (14.3%) | 2 (14.3%) |
Previous VTE event | 12 (7.6%) | 2 (16.7%) | 1 (8.3%) |
Smoking | 30 (18.9%) | 7 (23.3%) | 2 (6.6%) |
Pervious risk factor for VTE | 25 (15.9%) | 2 (8%) | 4 (16%) |
Chemotherapy type | |||
Fluropyrimidine containing | 127 (80.3%) | 21 (16.5%) | 21 (16.5%) |
Fluropyrimidine non-containing | 31 (19.7%) | 2 (6.4%) | 2 (6.4%) |
Prior PICC line in last 6 months | 13 (8.2%) | 1 (7.7%) | 4 (30.8%) |